Cargando…

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models

BACKGROUND: The second generation antipsychotic drugs represent the most common form of pharmacotherapy for schizophrenia disorders. It is now well established that most of the second generation drugs cause metabolic side-effects. Risperidone and its active metabolite paliperidone (9-hydroxyrisperid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyda, Heidi N., Procyshyn, Ric M., Tse, Lurdes, Yuen, Jessica W. Y., Honer, William G., Barr, Alasdair M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842964/ https://www.ncbi.nlm.nih.gov/pubmed/33508013 http://dx.doi.org/10.1371/journal.pone.0246211

Ejemplares similares

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
por: Boyda, Heidi N., et al.
Publicado: (2013)

Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines
por: Boyda, Heidi N., et al.
Publicado: (2020)

Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance
por: Boyda, Heidi N., et al.
Publicado: (2022)

An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine
por: Wu, Claire, et al.
Publicado: (2014)

Association between Serum Lipids and Antipsychotic Response in Schizophrenia
por: Kim, David D., et al.
Publicado: (2019)

A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents
por: Dodsworth, Thomas, et al.
Publicado: (2018)

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review
por: Lian, Lulu, et al.
Publicado: (2022)

A Focused Review of the Metabolic Side-Effects of Clozapine
por: Yuen, Jessica W. Y., et al.
Publicado: (2021)

Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review
por: Yuen, Jessica W. Y., et al.
Publicado: (2018)

Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis
por: Lee, Lik Hang N., et al.
Publicado: (2018)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
por: Yin, John, et al.
Publicado: (2017)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Comparative Pharmacology of Risperidone and Paliperidone
por: Corena-McLeod, Maria
Publicado: (2015)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

A retrospective study of antipsychotic drug switching in a pediatric population
por: Linton, David, et al.
Publicado: (2013)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Audit on prolactin monitoring for patients on oral risperidone, intramuscular risperidone, and intramuscular paliperidone
por: Bader, Mohamed
Publicado: (2021)

Reduction in Substance-Related Composite Harm Scores Through Street Soccer
por: Bates, Alan T, et al.
Publicado: (2023)

Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone
por: Korell, J, et al.
Publicado: (2017)

M216. ASSOCIATIONS OF EXTRAPYRAMIDAL SYMPTOMS WITH PSYCHOTIC SYMPTOMS IN A COHORT OF HOMELESS OR PRECARIOUSLY HOUSED PERSONS WITH OR WITHOUT SCHIZOPHRENIA
por: Kim, David, et al.
Publicado: (2020)

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone
por: Johnsen, Erik, et al.
Publicado: (2010)

Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children
por: Bahr, S M, et al.
Publicado: (2015)

Evidence based administration of risperidone and paliperidone for the treating conduct disorder
por: Ghanizadeh, Ahmad
Publicado: (2013)

Efficacy and tolerability of aripiprazole versus D(2) antagonists in the early course of schizophrenia: a systematic review and meta-analysis
por: Kim, David D., et al.
Publicado: (2021)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Developing prediction models for symptom severity around the time of discharge from a tertiary-care program for treatment-resistant psychosis
por: Lee, Lik Hang N., et al.
Publicado: (2023)

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
por: Schreiner, A, et al.
Publicado: (2015)

Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness
por: Lang, Donna J., et al.
Publicado: (2013)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection
por: Tang, Victor M., et al.
Publicado: (2015)

Improving Metabolic and Cardiovascular Health at an Early Psychosis Intervention Program in Vancouver, Canada
por: Fredrikson, Diane H., et al.
Publicado: (2014)

Risperidone-Induced Tardive Akathisia: A Rare Antipsychotic Side Effect with Management Issues
por: Mishra, Biswa Ranjan, et al.
Publicado: (2019)

Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report
por: Berle, Jan Øystein, et al.
Publicado: (2013)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

Retraction: Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report
por: Berle, Jan Øystein, et al.
Publicado: (2013)

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes
por: Hsia, Stephanie L., et al.
Publicado: (2018)

Second-generation antipsychotics and metabolic side-effects: Canadian population-based study
por: Hirsch, Lauren, et al.
Publicado: (2018)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qbneeffluah1rbm8fatqd6ku5d